+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rosacea - Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4661524
  • Drug Pipelines
  • 120 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • Accuitis, Inc.
  • Allergan
  • BioPharmX, Inc.
  • Cutanea Life Sciences
  • Dermata Therapeutics
  • Dr. Reddy's Laboratories
  • MORE
‘Rosacea - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Rosacea in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Rosacea from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Rosacea - Disease Understanding and Treatment Algorithm

The Rosacea market report gives the thorough understanding of the Rosacea by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Rosacea in the US, Europe, and Japan.

Rosacea Epidemiology

The Rosacea epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Prevalent population, Gender specific prevalence, Diagnosed prevalent population, Sub-type specific diagnosed prevalence and Severity-Specific diagnosed prevalence] scenario of Rosacea in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to this research, the total prevalent population of Rosacea was found to be 47,359,758, in the year 2016.

Rosacea Drug Chapters

This segment of the Rosacea report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market of Rosacea is mainly accounted by the use of Rhofade, Oracea, Mirvaso, Finacea, Soolantra, and Metrogel. Certain off-label therapies such as Brimonidine, Doxycycline, Tetracycline and others are also used for the treatment of Rosacea. Detailed chapters of upcoming therapies such as FMX103 (Foamix Pharmaceuticals), VERED (Sol-Gel), Omiganan (Cutanea Life Sciences) and BPX-04 (BioPharmaX) which are expected to launch during the forecast period have also been covered in the report.

Rosacea Market Outlook

The Rosacea market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the total market size of Rosacea in 7MM was found to be USD 494.4 million in 2016.

Rosacea Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Rosacea Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Rosacea Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake
Rosacea Report Assessment
  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Rosacea market
  • Organize sales and marketing efforts by identifying the best opportunities for Rosacea market
  • To understand the future market competition in the Rosacea market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Accuitis, Inc.
  • Allergan
  • BioPharmX, Inc.
  • Cutanea Life Sciences
  • Dermata Therapeutics
  • Dr. Reddy's Laboratories
  • MORE
1. Key Insights

2. Rosacea: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Rosacea in 2016
2.2. Total Market Share (%) Distribution of Rosacea in 2027

3. Disease Background and Overview: Rosacea
3.1. Introduction
3.2. Signs and Symptoms
3.3. Classification of Rosacea
3.4. Stages and GRADE
3.5. Pathophysiology
3.6. Genetic Basis of Rosacea according to Genome-Wide Association Study
3.7. Causes and Risk factors for Rosacea
3.8. Risk Factors
3.9. Diagnosis

4. Epidemiology and Patient Population
4.1. Key Findings

5. 7MM Total Prevalent Patient Population of Rosacea

6. 7MM Total Diagnosed Prevalent Patient Population of Rosacea

7. Country Wise-Epidemiology of Rosacea Disease
7.1. United States
7.1.1. Assumptions and Rationale
7.1.2. Total Prevalent Population of Rosacea in the United States
7.1.3. Gender-Specific Prevalent Population of Rosacea in the United States
7.1.4. Total Diagnosed Prevalent Population of Rosacea in the United States
7.1.5. Sub - Type Specific Diagnosed Prevalence of Rosacea in the United States
7.1.6. Severity - Specific Diagnosed Prevalent Population of Rosacea in United States
7.2. EU5 Countries
7.2.1. Assumptions and Rationale
7.3. Germany
7.3.1. Total Prevalent Population of Rosacea in Germany
7.3.2. Gender-Specific Prevalent Population of Rosacea in Germany
7.3.3. Total Diagnosed Prevalent Population of Rosacea in Germany
7.3.4. Sub - Type Specific Diagnosed Prevalence of Rosacea in Germany
7.3.5. Severity - Specific Diagnosed Prevalent Population of Rosacea in Germany
7.4. France
7.4.1. Total Prevalent Population of Rosacea in France
7.4.2. Gender-Specific Prevalent Population of Rosacea in France
7.4.3. Total Diagnosed Prevalent Population of Rosacea in France
7.4.4. Sub - Type Specific Diagnosed Prevalence of Rosacea in France
7.4.5. Severity - Specific Diagnosed Prevalent Population of Rosacea in France
7.5. Italy
7.5.1. Total Prevalent Population of Rosacea in Italy
7.5.2. Gender-Specific Prevalent Population of Rosacea in Italy
7.5.3. Total Diagnosed Prevalent Population of Rosacea in Italy
7.5.4. Sub - Type Specific Diagnosed Prevalence of Rosacea in Italy
7.5.5. Severity - Specific Diagnosed Prevalent Population of Rosacea in Italy
7.6. Spain
7.6.1. Total Prevalent Population of Rosacea in Spain
7.6.2. Gender-Specific Prevalent Population of Rosacea in Spain
7.6.3. Total Diagnosed Prevalent Population of Rosacea in Spain
7.6.4. Sub - Type Specific Diagnosed Prevalence of Rosacea in Spain
7.6.5. Severity - Specific Diagnosed Prevalent Population of Rosacea in Spain
7.7. United Kingdom
7.7.1. Total Prevalent Population of Rosacea in the United Kingdom
7.7.2. Gender-Specific Prevalent Population of Rosacea in the United Kingdom
7.7.3. Total Diagnosed Prevalent Population of Rosacea in the United Kingdom
7.7.4. Sub - Type Specific Diagnosed Prevalence of Rosacea in the United Kingdom
7.7.5. Severity - Specific Diagnosed Prevalent Population of Rosacea in United Kingdom
7.8. Japan
7.8.1. Assumptions and Rationale
7.8.2. Total Prevalent Population of Rosacea in Japan
7.8.3. Gender-Specific Prevalent Population of Rosacea in Japan
7.8.4. Total Diagnosed Prevalent Population of Rosacea in Japan
7.8.5. Sub - Type Specific Diagnosed Prevalence of Rosacea in Japan
7.8.6. Severity - Specific Diagnosed Prevalent Population of Rosacea in Japan

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Marketed Drugs
10.1. Rhofade: Allergan
10.1.1. Drug Description
10.1.2. Mechanism of Action
10.1.3. Regulatory Milestones
10.1.4. Product Developmental Activities
10.1.5. Advantages & Disadvantages
10.1.6. Safety and Efficacy
10.1.7. Product Profile
10.2. Oracea: Galderma Laboratories (Nestle Skin Health)
10.2.1. Drug Description
10.2.2. Mechanism of Action
10.2.3. Regulatory Milestones
10.2.4. Product Developmental Activities
10.2.5. Advantages & Disadvantages
10.2.6. Safety and Efficacy
10.2.7. Product Profile
10.3. Mirvaso: Galderma Laboratories (Nestle Skin Health)
10.3.1. Drug Description
10.3.2. Mechanism of Action
10.3.3. Regulatory Milestones
10.3.4. Product Developmental Activities
10.3.5. Advantages & Disadvantages
10.3.6. Safety and Efficacy
10.3.7. Product Profile
10.4. Finacea: Bayer
10.4.1. Drug Description
10.4.2. Mechanism of Action
10.4.3. Regulatory Milestones
10.4.4. Other Development Activities
10.4.5. Advantages & Disadvantages
10.4.6. Safety and Efficacy
10.4.7. Product Profile
10.5. Soolantra: Galderma Laboratories, Inc. (Nestle Skin Health)
10.5.1. Drug Description
10.5.2. Mechanism of Action
10.5.3. Regulatory Milestones
10.5.4. Other Development Activities
10.5.5. Advantages & Disadvantages
10.5.6. Safety and Efficacy
10.5.7. Product Profile
10.6. Metrogel: Galderma Laboratories (Nestle Skin Health)
10.6.1. Drug Description
10.6.2. Mechanism of Action
10.6.3. Regulatory Milestones
10.6.4. Product Developmental Activities
10.6.5. Advantages & Disadvantages
10.6.6. Safety and Efficacy
10.6.7. Product Profile

11. Key Cross Competition

12. Emerging Drugs
12.1. FMX103: Foamix Pharmaceuticals
12.1.1. Product Description
12.1.2. Other Developmental Activities
12.1.3. Clinical Development
12.1.4. Safety and Efficacy
12.1.5. Advantages and Disadvantages
12.1.6. Product Profile
12.2. Epsolay: Sol-Gel
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Clinical Trials Information
12.2.5. Safety and Efficacy
12.2.6. Advantages and Disadvantages
12.2.7. Product Profile
12.3. Omiganan: Cutanea Life Sciences
12.3.1. Product Description
12.3.2. Other Developmental Activities
12.3.3. Clinical Development
12.3.4. Safety and Efficacy
12.3.5. Product Profile
12.4. BPX-04: BioPharmX, Inc.
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Development
12.4.4. Safety and Efficacy
12.4.5. Advantages and Disadvantages
12.4.6. Product Profile
12.5. ACU-D1: Accuitis, Inc.
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Development
12.5.4. Advantages and Disadvantages
12.5.5. Product Profile
12.6. HY01 (Minocycline): Hovione Scientia Limited
12.6.1. Product Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Development
12.6.4. Advantages and Disadvantages
12.6.5. Product Profile
12.7. DFD-04: Dr. Reddy's Laboratories
12.7.1. Product Description
12.7.2. Clinical Development
12.7.3. Product Profile
12.8. DFD-29: Dr. Reddy's Laboratories
12.8.1. Product Description
12.8.2. Clinical Development
12.8.3. Product Profile
12.9. DMT210: Dermata Therapeutics
12.9.1. Product Description
12.9.2. Other Developmental Activities
12.9.3. Clinical Development
12.9.4. Safety and Efficacy
12.9.5. Advantages and Disadvantages
12.9.6. Product Profile

13. Rosacea: 7 Major Market Analysis
13.1. Key Findings
13.2. Market Size of Rosacea in 7MM

14. The United States Market Outlook
14.1. United States Market Size
14.1.1. Total Market size of Rosacea
14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook
15.1. Germany
15.1.1. Total Market size of Rosacea in Germany
15.1.2. Market Size by Therapies
15.2. France
15.2.1. Total Market size of Rosacea
15.2.2. Market Size by Therapies
15.3. Italy
15.3.1. Total Market size of Rosacea
15.3.2. Market Size by Therapies
15.4. Spain
15.4.1. Total Market size of Rosacea
15.4.2. Market Size by Therapies
15.5. United Kingdom
15.5.1. Total Market size of Rosacea
15.5.2. Market Size by Therapies

16. Japan: Market Outlook
16.1. Total Market size of Rosacea
16.2. Market Size by Therapies

17. Market Drivers

18. Market Barriers

19. Appendix
19.1. Report Methodology

20. The Publisher's Capabilities

21. Disclaimer

22. About the Publisher
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan
  • Galderma Laboratories (Nestle Skin Health)
  • BayerFoamix Pharmaceuticals
  • Sol-Gel
  • Cutanea Life Sciences
  • BioPharmX, Inc.
  • Accuitis, Inc.
  • Hovione Scientia Limited
  • Dr. Reddy's Laboratories
  • Dermata Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll